Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists

By sjmartinez • August 15, 2024

Rastogi A, Collins A, Kelepouris E, Kotzker W, Middleton JP, Rajpal M, Roy-Chaudhury P, Chertow GM. Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists. J Prim Care Community Health. 2024 Jan-Dec;15:21501319241259905. doi: 10.1177/21501319241259905. PMID: 39143759.

Tags: Chronic kidney disease, consensus, KDIGO, Nephrology, Publications, SGLT2 inhibitor, treatment algorithm

Intravitreal vascular endothelial growth factor inhibitor systemic and renal toxicity registry

Nguyen MD, Fekrat R, Gee C, Demirci AN, Kharabaf S, Le D, Tadros M, Nguyen VQ, Patel S, Truong T, Ahdoot R, Kurtz IB, Kerr[...]

Management recommendations for kidney transplantation in patients with plasma cell dyscrasia

Murakami N, Blosser CD, Webber AB, Gupta G, Singh N, Boppana S, Master S, Parasuraman R, Campagnaro EL, Java A, Sprangers B, Bhasin-Chhabra B, Lum[...]

Experiences and perspectives of patients and their caregivers on gastrointestinal symptoms in peritoneal dialysis: Workshop report

Hayat A, Johnson DW, Manera K, Viecelli AK, Wilkie M, Shen J, Wang AY, Htay H, Jaure A, Cho Y, Walker R. Experiences and perspectives[...]